Mental Health Clinics in Portland, TX Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Coastal Plains Community Center Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 200 Marriott Dr, Portland, TX 78374 Phone: 361-777-3991 Fax: 361-777-0610 |
Richard L Reitmann Lpc Pllc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1700 Wildcat Dr Ste D, Portland, TX 78374 Phone: 361-445-4080 |
Coastal Plains Community Center Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 200 Marriott Drive, Portland, TX 78374 Phone: 361-777-3991 Fax: 361-777-0610 |
Coastal Plains Community Mhmr Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 200 Marriott Dr, Portland, TX 78374 Phone: 361-777-3991 |
Mary Ann Gansle Sole Mbr Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1700 Wildcat Dr Ste D, Portland, TX 78374 Phone: 361-445-4080 Fax: 888-413-3010 |
Coastal Plains Community Center Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 200 Marriott Dr, Portland, TX 78374 Phone: 361-777-3991 Fax: 361-777-0610 |
News Archive
Scientists move closer to understanding HIV-1 infection
Scientists have long been unable to fully explain how infections attack the body, but now a team of researchers, including one from the University of Central Florida, has taken a step closer to understanding how the process works in HIV-1. The results mean that one day that knowledge may prevent infection.
Multimedia programs increase vegetable intake in kindergarten children
Popeye cartoons, tasting parties and junior cooking classes can help increase vegetable intake in kindergarten children, according to new research published in the journal Nutrition & Dietetics.
Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer's
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company's lead compound for Alzheimer's disease.
Positive results from new analyses of denosumab Phase 3 trials
Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.
› Verified 1 days ago